Business
vTv Therapeutics and M42’s IROS Announce Submission of Phase 2 Clinical Study Protocol for Cadisegliatin in Type 2 Diabetes to the United Arab Emirates Department of Health
Trial to assess cadisegliatin as potential adjunctive therapy to insulin in patients with T2DHIGH POINT, N.C., Dec. 18, 2025 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a late-stage biopharmaceutical company, today announced a Phase 2 clinical study protocol developed in collaboration with M42’s Insights Research Organization & Solutions (IROS), a leading United Arab Emirates (UAE)-based contract research organization, has been submitted to the Department of Health (DOH) Abu Dhabi.
About this update from Vtv Therapeutics Inc.
[{"type":"image","alt":"vTv Therapeutics Inc.","displaySize":"","headline":null,"caption":"vTv Therapeutics Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":156,"url":"https://media.zenfs.com/en/globenewswire.com/6b6b541287fc9ae12df42673a7e33331"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/AM4EHLX89ULuROtlqZ7i2w--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTIxODtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/6b6b541287fc9ae12df42673a7e33331","width":300,"height":156}},"lazy":false},{"type":"text","content":"Trial to assess cadisegliatin as potential adjunctive therapy to insulin in patients with T2D","length":93,"tagName":"p"},{"type":"text","content":"HIGH POINT, N.C., Dec. 18, 2025 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a late-stage biopharmaceutical company, today announced a Phase 2 clinical study protocol developed in collaboration with M42’s Insights Research Organization & Solutions (IROS), a leading United Arab Emirates (UAE)-based contract research organization, has been submitted to the Department of Health (DOH) Abu Dhabi. The study is designed to evaluate the safety and efficacy of cadisegliatin, a potential first-in-class oral adjunctive therapy to insulin, in people living with type 2 diabetes. This study constitutes the longest trial investigating cadisegliatin to date and will be a 12-month, double-blind, randomized, placebo-controlled trial enrolling approximately 300 patients with type 2 diabetes who are treated with insulin for glycemic control. Participants will be randomized into three arms: two cadisegliatin dose groups (400 mg and 800 mg once daily) and a placebo control group. The trial will take place in the UAE, Jordan, and Tunisia, with the first patient first visit expected in the first quarter of 2026.","length":1127,"tagName":"p"},{"type":"text","content":"“Through our collaboration with M42, we continue to investigate cadisegliatin’s potential as an adjunctive therapy to insulin for people living with diabetes,” said Paul Sekhri, Chairman, President, and CEO of vTv Therapeutics. “This study also expands the potential geographic footprint for cadisegliatin.”","length":307,"tagName":"p"},{"type":"text","content":"“The launch of this trial enables us to evaluate the safety and efficacy of cadisegliatin over the course of one year in people with insulin-...